This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS).
We carried out a randomized, double-blind placebo-controlled trial of allogeneic bone marrow derived human mesenchymal stromal cells for treatment of moderate to severe ARDS in 60 patients, 40 MSC and 20 placebo, in a 2:1 randomization. This trial is the extension of the Phase 1 pilot trial (NCT01775774). Patients were followed daily for adverse events through day 28, death or hospital discharge, whichever occurs first. Vital status was collected at 6 and 12 months after study enrollment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes.
University of California San Francisco
San Francisco, California, United States
Stanford University
Stanford, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Minnesota Medical Center
Saint Paul, Minnesota, United States
Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion
Within 6 h of study product infusion: * Increase in vasopressor dose to the following values or higher: * Norepinephrine 10 μg/min * Phenylephrine 100 μg/min * Dopamine 10 μg/kg per min * Epinephrine 0.1 μg/kg per min or addition of a third vasopressor * New ventricular tachycardia, ventricular fibrillation or asystole * New cardiac arrhythmia requiring cardioversion * Hypoxaemia requiring an increase in FiO2 of 0·2 or more and an increase in PEEP of 5·0 or more to maintain SpO2 in the target range of 88-95% * Clinical scenario consistent with transfusion incompatibility or transfusion-related infection (eg, urticaria, new bronchospasm)
Time frame: 6 hours
Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion
Within 24 h of study product infusion • Any cardiac arrest or death
Time frame: 24 hours
Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)
Safety endpoint: Any unexpected severe adverse events in two groups
Time frame: 12 months
PaO2:FiO2 Change From Baseline to Day 3
Efficacy endpoint: PaO2:FiO2 change from baseline to day 3
Time frame: baseline and day 3
Lung Injury Score From Baseline to Day 3
Murray score for acute lung injury. The range is 0 to 4. The higher score, the worst outcome.
Time frame: baseline and day 3
Oxygenation Index Change From Baseline to Day 2
Oxygenation index with the following validated measure of respiratory function: FiO2 (%) x mean airway pressure / PaO2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ohio State University
Columbus, Ohio, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Time frame: baseline and day 2
SOFA Score Change From Baseline to Day 3
Sequential organ failure assessment score (SOFA). The SOFA score ranges from 0 to 24. The higher, the worse.
Time frame: baseline and day 3
Number of Patients Death to Day 28
Efficacy endpoint: all-cause mortality at day 28
Time frame: 28 days
Mortality to Day 60
Efficacy endpoint: all-cause mortality at day 60
Time frame: 60 days
Number of Ventilator-free Days to Day 28
Efficacy endpoint: Number of ventilator-free days to day 28.
Time frame: 28 days
Non-pulmonary Organ-failure-free Days to Day 28
Efficacy endpoint: Non-pulmonary organ-failure-free days to day 28
Time frame: 28 days
Angiopoietin 2 Change From Baseline to 6 h
Biological markers of endothelial injury: angiopoietin 2
Time frame: baseline and 6 hours
Angiopoietin 2 Change From Baseline to 24 h
Biological markers of endothelial injury: angiopoietin 2
Time frame: baseline and 24 hours
Interleukin 6 Change From Baseline to 6 h
Biological markers of inflammation: interleukin 6
Time frame: baseline and 6 hours
Interleukin 6 Change From Baseline to 24 h
Biological markers of inflammation: interleukin 6
Time frame: baseline and 24 hours
Interleukin 8 Change From Baseline to 6 h
Biological markers of inflammation: interleukin 8
Time frame: baseline and 6 hours
Interleukin 8 Change From Baseline to 24 h
Biological markers of inflammation: interleukin 8
Time frame: baseline and 24 hours
RAGE Change From Baseline to 6 h
Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)
Time frame: baseline and 6 hours
RAGE Change From Baseline to 24 h
Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)
Time frame: baseline and 24 hours